Biopharmaceutical company Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) on Wednesday announced the acquisition of avexitide, a novel GLP-1 receptor antagonist, from Eiger BioPharmaceuticals Inc.
Avexitide has received FDA Breakthrough Therapy Designation for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism (HI).
The GLP-1 receptor antagonist has shown significant efficacy in reducing severe hypoglycemic events in Phase 2 trials for PBH, achieving FDA-supported primary endpoints. Phase 3 trials for PBH are expected to commence in Q1 2025, with data anticipated in 2026. Avexitide demonstrated a favorable safety profile across five clinical trials.
Amylyx plans to integrate avexitide into its pipeline, which includes treatments for Wolfram syndrome, progressive supranuclear palsy and amyotrophic lateral sclerosis (ALS). The acquisition aligns with Amylyx's focus on addressing high unmet medical needs.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA